Redeye reviews the case of Saniona following continued positive progress lately. 2022 has been a turbulent year for the company, including a major restructuring of the management team, stopped clinical trials in Tesomet and a stronger focus on business development. Saniona was put in a precarious situation, but we argue that the new management team has done the right things so far and we again feel confident to dig deeper into the fundamental value of the company's assets. We raise our base case to SEK 6.5, to again reflect the potential in Tesomet and also include a more thorough take on SAN711.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.